27.68

0.81% -0.225

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Discussions Forecast

Immunovant Inc stock is traded at $27.68, with a volume of 752.00K. It is down -0.81% in the last 24 hours and down -24.49% over the past month. Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Previous Close:

$27.90

Open:

$28.03

24h Volume:

752.00K

Relative Volume:

0.50

Market Cap:

$5.72B

Revenue:

Net Income/Loss:

$-505.61M

P/E Ratio:

-9.9921

EPS:

-2.7697

Net Cash Flow:

$-407.32M

1W Performance:

-8.54%

1M Performance:

-24.49%

6M Performance:

+0.89%

1Y Performance:

+54.35%

1-Day Range:

$27.61

$28.33

1-Week Range:

$27.83

$30.64

52-Week Range:

$16.77

$45.42

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

917-410-3120

Address

1000 PARK FORTY PLAZA, DURHAM, NY

Employee

315

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMVT Immunovant Inc	27.68	5.72B	0	-505.61M	-407.32M	-2.7697
VRTX Vertex Pharmaceuticals Inc	510.13	129.30B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.70	94.90B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.21	82.49B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.03	53.33B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	370.95	41.96B	5.76B	514.49M	1.10B	4.4813

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Mkt Perform
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-14-25	Initiated	Truist	Hold
Jul-10-25	Resumed	Goldman	Neutral
Mar-03-25	Initiated	Jefferies	Hold
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform
Oct-09-24	Reiterated	Oppenheimer	Outperform
Mar-28-24	Initiated	Oppenheimer	Outperform
Mar-13-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	JP Morgan	Overweight
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Oct 09, 2026

Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com South Africa

Oct 09, 2026

Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com Canada

Oct 09, 2026

Immunovant COO Melanie Gloria sells shares worth $71,846 By Investing.com - Investing.com South Africa

Oct 09, 2026

Form 4 Immunovant Inc For: 9 October By Investing.com - Investing.com South Africa

Oct 09, 2026

Form 4 Immunovant Inc For: 9 October - Investing.com India

Oct 09, 2026

Immunovant COO Melanie Gloria sells shares worth $71,846 - Investing.com India

Oct 09, 2026

Oct 06, 2026

Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Nigeria

Oct 06, 2026

Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com South Africa

Oct 06, 2026

Oct 05, 2026

Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Canada

Oct 05, 2026

Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com Canada

Oct 05, 2026

Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com UK

Oct 05, 2026

Sep 26, 2026

Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media

Sep 26, 2026

Sep 11, 2026

How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 11, 2026

Sep 03, 2026

Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media

Sep 03, 2026

Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn

Sep 03, 2026

Sep 01, 2026

Roivant Sciences (ROIV) president sells 200,000 shares under preset plan - Stock Titan

Sep 01, 2026

Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Sep 01, 2026

Aug 24, 2026

Roivant (NASDAQ: ROIV) president settles RSU taxes in shares - Stock Titan

Aug 24, 2026

Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com

Aug 24, 2026

Aug 22, 2026

Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn

Aug 22, 2026

Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseStraddle Setup - dars.gov.et

Aug 22, 2026

Aug 20, 2026

Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus

Aug 20, 2026

Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments 79wfgdDXy - Villa de la Orotava

Aug 20, 2026

immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava

Aug 20, 2026

Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn

Aug 20, 2026

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar

Aug 20, 2026

Aug 19, 2026

Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments BI2Y6DHdO - scchr.jp

Aug 19, 2026

Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang

Aug 19, 2026

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PR Newswire

Aug 19, 2026

Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn

Aug 19, 2026

Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingSign of Strength - dars.gov.et

Aug 19, 2026

Aug 16, 2026

Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn

Aug 16, 2026

GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat

Aug 16, 2026

Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat

Aug 16, 2026

Aug 15, 2026

Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn

Aug 15, 2026

Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat

Aug 15, 2026

Aug 14, 2026

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st

Aug 14, 2026

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st

Aug 14, 2026

Aug 13, 2026

Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com

Aug 13, 2026

Aug 12, 2026

Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com South Africa

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Nigeria

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD - Investing.com

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Canada

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com India

Aug 12, 2026

Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com UK

Aug 12, 2026

The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com

Aug 12, 2026

Aug 11, 2026